News

Physical exercise may help reduce inflammation in multiple sclerosis (MS) by changing the activity of immune T-cells, a new study reports. Findings suggest this effect may depend in part on signaling through the vagus nerve, which connects the brain to other organs and helps regulate automatic bodily functions.

Urinary issues are a frequent and distressing reality for women with multiple sclerosis (MS), and new research suggests these symptoms may diminish quality of life, specifically by fueling feelings of loneliness. While the physical burden of bladder dysfunction is well-documented, this study highlights a critical emotional link, suggesting that…

The first participant has been dosed in a Phase 1 clinical trial testing TNV262, an experimental therapy that Tenvie Therapeutics is developing as a potential treatment for multiple sclerosis (MS) and other conditions including obesity and cardiovascular disease. The Phase 1a/1b study will test single and multiple doses…

While doctors and specialists view “high-quality” multiple sclerosis (MS) care through the lens of effective treatments and faster diagnosis, patients have a different priority: being heard, according to a recent study. Researchers interviewed a range of specialists and patients to bridge the gap in how these groups define excellence…

A history of infectious mononucleosis, often called “mono,” more than triples the risk of developing multiple sclerosis (MS), according to a new study. While scientists have long suspected a link between the Epstein-Barr virus (EBV) and MS, these findings provide evidence that a documented case of mono serves…

Exposure to higher levels of ground-level ozone may significantly increase the risk that children and teens will develop multiple sclerosis (MS), a new Italian study suggests. Researchers found that for every unit increase in ozone levels in the three years preceding the first MS symptoms, the likelihood of…

A pair of studies showed that a group of nerve cells essential for cognition may be particularly vulnerable to damage in multiple sclerosis (MS). Researchers found that CUX2 neurons — specialized cells in the brain’s cortex, which governs complex thinking — are…

A 12-week intervention combining breathing exercises, cold exposure, and meditation — known as the Wim Hof Method (WHM) — or a lifestyle intervention aimed at improving physical activity and dietary habits may help reduce inflammation linked to disease progression in people with multiple sclerosis (MS), a pilot study suggests.

In multiple sclerosis (MS), certain disease-driving immune cells carry a protein marker called CD29, which helps them move into the brain and trigger inflammation. That is the key finding of a new study by researchers in the Netherlands, who zeroed in on the protein as a driver of MS.

The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multiple sclerosis (MS). Optic neuritis, marked by inflammation of the optic nerve that carries signals between the eyes and the brain, can…

A new model of nerve fibers may serve as a platform to screen for experimental treatments that can promote myelin repair in multiple sclerosis (MS), a study showed. The model is made of soft micropillars around which myelin-producing cells can wrap myelin. Researchers found that some drugs tended to…

Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase 2 clinical trial of Lucid-MS, a “first-in-class” oral therapy designed to halt the progression of multiple sclerosis (MS) by protecting myelin, or the protective sheath around nerves in…

MS Canada is inviting cyclists across the country to take part in its 2026 MS Bike season, a series of fundraising rides aimed at supporting Canadians living with multiple sclerosis (MS). The annual MS Bike series brings together thousands of participants to ride scenic routes while raising money…

The cells that line the inside of the gut — known as intestinal epithelial cells — may play a key role in triggering inflammation that drives multiple sclerosis (MS), a study showed. The study found that these cells can activate a type of T-cell known as Th17 cells. These…

More than 70% of people with multiple sclerosis (MS) receiving outpatient rehabilitation take at least five medications — often including vitamin supplements and drugs used to manage symptoms such as muscle stiffness, pain, and mental health issues — to treat their MS. That’s according to a real-world study in…

A new study being funded by the National Multiple Sclerosis Society (NMSS) will seek to better understand how women with multiple sclerosis (MS) navigate menopause and develop resources to address gaps in care. The study, “The Menopausal Transition, MS Symptom Management, and Multidisciplinary Care Gaps,” will use input from…

Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims to slow myelin loss — which ultimately results in the neurological problems that drive multiple sclerosis (MS) — in people with the progressive…

Multiple sclerosis (MS) has become far more common in England over the past two decades, but people diagnosed more recently are living longer, according to a study led by University College London (UCL). The shift reflects major advances in MS diagnosis and care. But researchers found that social…

Variations in the activity of a protein called p21 may underlie the differences in the activity of myelin-repairing cells in the brains of people with multiple sclerosis (MS), according to a new study. The findings may help to explain why different people with MS develop different forms of…

Exercises to strengthen the respiratory muscles — the muscles in the chest needed to move air in and out of the lungs when breathing — can help improve lung function in people with multiple sclerosis (MS), according to a new analysis. This type of exercise, known as respiratory muscle…

IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was well tolerated in healthy volunteers when given at single increasing doses. The findings come from the single-ascending dose portion of an ongoing Phase 1 clinical trial (NCT06637865), which tested…

An experimental therapy designed to eliminate harmful B-cells — key drivers of inflammation in multiple sclerosis (MS) and other autoimmune diseases — has reached an early development milestone. The treatment candidate, CDR111, is being developed under a collaboration between CDR-Life and Boehringer Ingelheim. The milestone was achieved…

When Brenda Snow started experiencing vertigo, vision problems, and other symptoms in the early 1990s, she visited several doctors. However, as often happens with complex conditions, she struggled to have her concerns validated. Snow, who lived in Northern California at the time, didn’t give up. She continued looking for answers…

The Accelerated Cure Project for Multiple Sclerosis (ACP) has received funding to help interpret and share findings from the DISCO-MS study, which examined whether older adults with stable multiple sclerosis (MS) could stop disease-modifying medications, to support more informed treatment decisions. The award comes through the Eugene Washington…

Brain atrophy, or the loss of brain volume, in people with relapsing-remitting multiple sclerosis (RRMS) appears to slow with age, according to data from more than 4,000 patients who took part in Phase 3 clinical trials. Researchers found that older adults with RRMS had significantly smaller brain volumes than…

Ludwig Kappos, MD, a neurologist and researcher at University Hospital in Basel, Switzerland, has been named the 2026 recipient of the John Dystel Prize for Multiple Sclerosis Research for his central role in advancing understanding and treatment of multiple sclerosis (MS) and monitoring of disease progression. The $40,000…

A combination of drugs widely used in anti-aging studies seems to compromise the function of the brain’s myelin-making cells and cause profound myelin loss, according to the findings of a new study in mice and lab-grown cells. The dual treatment, which combines dasatinib and quercetin, also known as D+Q, caused…

Close relatives of people with multiple sclerosis (MS) are 100 times more likely to develop the neurological disorder than the general population, according to a new analysis of GEMS data. Among participants in GEMS, a large-scale observational study assessing MS risk among family members, about half said…

The National Multiple Sclerosis Society has designated UC Davis Health in California as a new Center for Comprehensive MS Care, recognizing its ability to provide coordinated, multidisciplinary care for people with multiple sclerosis (MS). The designation is part of the society’s Network of MS Healthcare Professionals, which…

Innocare Pharma has dosed the first healthy volunteer in a clinical trial in China testing ICP-538, its oral treatment candidate for multiple sclerosis (MS) and other autoimmune diseases. The novel experimental therapy works by promoting the degradation of the VAV1 protein, essential for the function of T-cells and…